Research programme - fibrosis therapeutics - Galapagos
Alternative Names: GLPGxxxLatest Information Update: 28 Mar 2023
At a glance
- Originator Evotec SE
- Developer Evotec SE; Galapagos NV
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Fibrosis in Germany